title: Interferon apha 2b for treating patients with JAK2V617F positive polycythemia vera and essential thrombocytosis.
abstract: OBJECTIVE
  To investigate interferon (IFN) alpha 2 b for treating patients with JAK2V617F positive polycythemia vera (PV) and essential thrombocytosis (ET).
  
  
  METHODS
  Interferon alpha 2 b was used to treat patients with JAK2V617F positive PV and ET. In control group, hydroxyurea was used. Endpoint of study was to compare rates of hematological and molecular remission.
  
  
  RESULTS
  Patients in the interferon alpha 2 b group achieved higher rates of hematologic and molecular remission than patients in the hydroxyurea group, with a lower incidence of thrombosis.
  
  
  CONCLUSIONS
  Compared with hydroxyurea, interferon alpha 2 b could reduce JAK2V617F load for patients with PV and ET, and achieve higher molecular remission, improve treatment efficacy and reduce complications.
authors.affiliation: Department of Hematology, Affiliated Hospital of Taishan Medical University, Tai'an, China E-mail : zhirongzhang123@163.com.
authors.forename: Zhi-Rong
authors.initials: ZR
authors.lastname: Zhang
authors.forename: Yan-Chao
authors.initials: YC
authors.lastname: Duan
mesh_terms: D000328:Adult; D000368:Aged; D005260:Female; D006801:Humans; D006918:Hydroxyurea / Q000627:therapeutic use; D000077190:Interferon alpha-2; D016898:Interferon-alpha / Q000627:therapeutic use*; D053614:Janus Kinase 2 / Q000096:biosynthesis / Q000235:genetics*; D008297:Male; D008875:Middle Aged; D009154:Mutation; D011087:Polycythemia Vera / Q000188:drug therapy*; D011994:Recombinant Proteins / Q000627:therapeutic use; D013920:Thrombocythemia, Essential / Q000188:drug therapy*; D013927:Thrombosis / Q000453:epidemiology; D016896:Treatment Outcome
chemical_list: D000077190:Interferon alpha-2; D016898:Interferon-alpha; D011994:Recombinant Proteins; C507924:JAK2 protein, human; D053614:Janus Kinase 2; D006918:Hydroxyurea